Alliances At-A-Glance left
Daiichi Sankyo and Amplimmune, Inc., a biotechnology company based in Gaithersburg, Maryland, entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein). The collaboration focuses on the development of AMP-110, a potential immune modulation therapy for autoimmune diseases.
Daiichi Sankyo and Coherus BioSciences, Inc., a biotechnology company based in Redwood City, California, entered into an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in Japan and other Asian countries.
Daiichi Sankyo and GSK Japan entered into a strategic alliance and formed a vaccine joint venture in Japan. Daiichi Sankyo and GSK Invested equally new therapeutic protein, AMP-110 (B7-H4 fusion protein). The collaboration focuses on the development of AMP-110, a potential immune modulation therapy for autoimmune diseases.
Daiichi Sankyo and Mitsubishi Tanabe Pharma Corporation formed a strategic sales alliance to conduct joint sales activities in Japan (post-approval) for several type 2 diabetes treatments, including DPP4 inhibitor, MP-513 (teneligliptin), SGLT2 inhibitor, and TA-7284 (canagliflozin), which are all being developed by Mitsubishi Tanabe Pharma.
Daiichi Sankyo and NGM Biopharmaceuticals, Inc., a biotechnology company based in South San Francisco, California, entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration, a potential treatment for certain types of diabetes.
Daiichi Sankyo and ArQule, a biotechnology company based in Woburn, Massachusetts, entered into a license agreement to develop a new AKT inhibitor called ARQ 092 – the first compound to emerge from the companies' November 2008 agreement to collaborate on research utilizing the AKIPTM (ArQule Kinase Inhibitor Platform) technology. Under the license agreement, Daiichi Sankyo obtained exclusive rights for the development, manufacturing and marketing of ARQ 092 on a worldwide basis.
Daiichi Sankyo and AstraZeneca announced a co-promotion agreement (upon approval) in Japan for denosumab for the treatment of bone disorders stemming from bone metastasis. Daiichi Sankyo acquired denosumab rights in Japan in 2007 from Amgen.
Daiichi Sankyo acquired Plexxikon, a privately held pharmaceutical company based in Berkeley, California with therapeutic research areas including oncology and CNS disorders, as well as auto-immune, neuro-inflammatory and cardio-renal diseases. This acquisition accelerated Daiichi Sankyo's entry into the oncology market by strengthening its pipeline. Through the acquisition, Daiichi Sankyo obtained certain co-promotion rights in the United States for ZELBORAF® (vemurafenib, PLX4032), which is jointly commercialized by Genentech.
Daiichi Sankyo and AstraZeneca announced a co-promotion agreement for NEXIUM® Capsule (esomeprazole magnesium), a Proton Pump Inhibitor in Japan. Both companies currently co-promote this product in Japan. AstraZeneca developed and manufactures NEXIUM®, while Daiichi Sankyo is responsible for its sales and distribution.
Daiichi Sankyo and ArQule announced two strategic R&D partnerships to progress the development and discovery of novel oncology therapeutics. Through the first partnership, they will co-develop tivantinib (ARQ 197), a proprietary, orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase, under investigation for the treatment of certain cancers. The second partnership will advance the application of ArQule's kinase inhibitor discovery platform (AKIPTM) to develop a new generation of highly selective, anti-cancer kinase inhibitors.
Daiichi Sankyo acquired U3 Pharma, a biotechnology company based in Martinsried, Germany. U3 Pharma's pipeline of novel targeted therapeutics includes programs focusing on fully-human antibodies as potential therapies for breast, lung and colorectal cancers, among others.
Daiichi Sankyo and Amgen, a biotechnology company based in Thousand Oaks, California, entered into a broad collaboration on the development and commercialization of denosumab, in Japan, for a broad range of bone loss conditions including osteoporosis and bone metastases.
Trademarks not owned by Daiichi Sankyo, Inc. are property of their respective owners.